Psoriasis News and Research

Latest Psoriasis News and Research

Soligenix acquires novel orphan drug candidate for treatment of CTCL

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the acquisition of a novel orphan drug candidate, known as SGX301 (synthetic hypericin).

8 Sep 2014

Microtechnologies to tackle problems of mobility industry and life sciences

CIC microGUNE, the Co-operative Research Centre into Microtechnologies, is coordinating the microSCALE project which seeks to generate innovative solutions based on microtechnologies to tackle the problems of the mobility industry and life sciences, among others.

28 Aug 2014

Cilag GmbH International acquires biopharmaceutical company, Covagen AG

Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has acquired Covagen AG, a privately-held, biopharmaceutical company specializing in the development of multispecific protein therapeutics through the FynomAb® technology platform.

25 Aug 2014

Lilly’s ixekizumab superior to placebo, etanercept on all skin clearance measures in Phase 3 studies

Eli Lilly and Company's investigational medicine ixekizumab was statistically superior to etanercept and placebo on all skin clearance measures in Phase 3 studies, the company said today in disclosing top-line results from its pivotal UNCOVER studies in moderate-to-severe plaque psoriasis.

22 Aug 2014

Research findings call for clinical testing of relevant drugs to prevent NASH

Non-alcoholic fatty liver disease (NAFLD) is a common affliction, affecting almost 30 percent of Americans, with a significant number suffering from its most severe form, called non-alcoholic steatohepatitis or NASH, which can lead to cirrhosis and liver cancer. In recent years, NASH has become the leading cause of liver transplantation.

19 Aug 2014

Experts examine how molecule in parasitic worms can effectively treat autoimmune diseases

Experts believe a molecule in parasitic worms could help explain why worm infections can effectively treat a range of autoimmune diseases, including multiple sclerosis, psoriasis, rheumatoid arthritis and lupus.

12 Aug 2014

3SBio enters into exclusive license with DiNonA for development of Leukotuximab

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with DiNonA Inc. for the development, manufacturing and marketing of Leukotuximab, an anti JL-1 antibody for acute leukemia (AL), including acute myelocytic leukemia (AML) and acute lymphoblastic leukemia (ALL), in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and the Middle East (excluding Cyprus, Egypt, Israel and Turkey).

8 Aug 2014

Dimethyl fumarate offers no added benefits for adults with RRMS

Dimethyl fumarate has been approved since January 2014 for adults with relapsing remitting multiple sclerosis.

8 Aug 2014

Idera collaborates with TMA to advance new potential treatment approach for myositis

Idera Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing nucleic acid therapeutics for patients with cancer and rare diseases, and The Myositis Association (TMA), the only nonprofit organization dedicated to solely serving all patients with inflammatory myopathies, today announced a collaboration to advance a new potential treatment approach for polymyositis and dermatomyositis known as Toll-like receptor (TLR) antagonism.

7 Aug 2014

Study: Nervous system and stress affect inflammatory skin conditions

Anyone who's had a pimple form right before an important event may wonder if stress caused the break out.

7 Aug 2014

Kinex receives FDA approval to begin Phase I study of KX2-391 Ointment for actinic keratosis

Kinex Pharmaceuticals announced the receipt of an allowance by the US FDA for the Company's KX2-391 Ointment for the commencement of a Phase I clinical study in actinic keratosis. This is the Company's third IND to be allowed by the US FDA in the past 12 months.

25 Jul 2014

Experts join together to call for better screening of psoriatic arthritis

Leading experts have joined together for the first time to call for better screening of psoriatic arthritis to help millions of people worldwide suffering from the condition.

24 Jul 2014

Early-career physicians receive National Psoriasis Foundation fellowship to study psoriasis

Twelve residents and medical students each received a one-year, $50,000 National Psoriasis Foundation fellowship to study psoriasis.

21 Jul 2014

13 researchers awarded National Psoriasis Foundation fellowship to study psoriasis

Twelve residents and medical students each received a one-year, $50,000 National Psoriasis Foundation fellowship to study psoriasis. The fellowships aim to increase the number of scientists studying and treating psoriatic disease by encouraging promising doctors to dedicate their careers to the study of psoriasis as physician researchers.

18 Jul 2014

Phase III research shows that new drug improves symptoms related to plaque psoriasis

Randomized, phase III research from the University of Alabama at Birmingham shows that a new drug improves symptoms related to moderate to severe plaque psoriasis, a chronic skin disease of scaling and inflammation.

17 Jul 2014

Thirteen scientists receive grant to identify new treatments, cure for psoriasis

Thirteen scientists received a total of $1.05 million in funding from the National Psoriasis Foundation for projects that aim to identify new treatments and a cure for psoriasis—an autoimmune disease that appears on the skin, affecting 7.5 million Americans—and psoriatic arthritis—an inflammatory arthritis that affects the joints and tendons, occurring in up to 30 percent of people with psoriasis.

16 Jul 2014

Johnson & Johnson sales increase 9.1% to $19.5 billion in second quarter 2014

Johnson & Johnson today announced sales of $19.5 billion for the second quarter of 2014, an increase of 9.1% as compared to the second quarter of 2013. Operational results increased 9.4% and the negative impact of currency was 0.3%.

15 Jul 2014

Metvix PDT now available at Odette Cancer Centre as additional treatment option for NMSC patients

The Odette Cancer Centre at Sunnybrook Health Sciences Centre in conjunction with Galderma Canada are pleased to announce that Metvix PDT (Photodynamic Therapy), is now available at the Odette Cancer Centre in Toronto as an additional treatment option for patients with NMSC (non-melanoma skin cancer).

15 Jul 2014

Medac Pharma's Rasuvo injection gets FDA approval for RA, pJIA and psoriasis

Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announced that the U.S. Food and Drug Administration has approved Rasuvo, a subcutaneous injectable methotrexate (MTX) therapy delivered in an auto-injector for rheumatoid arthritis (RA), polyarticular-course juvenile idiopathic arthritis (pJIA) and psoriasis.

14 Jul 2014

Dmitry Medvedev presents Russia's first national "Industry" award to BIOCAD

On July 9 Prime Minister of the Russian Federation Dmitry Medvedev, presented Russia's first national "Industry" award to a biopharmaceutical company BIOCAD.

11 Jul 2014

Psoriasis News and Research

Latest Psoriasis News and Research

Soligenix acquires novel orphan drug candidate for treatment of CTCL

Microtechnologies to tackle problems of mobility industry and life sciences

Cilag GmbH International acquires biopharmaceutical company, Covagen AG

Lilly’s ixekizumab superior to placebo, etanercept on all skin clearance measures in Phase 3 studies

Research findings call for clinical testing of relevant drugs to prevent NASH

Experts examine how molecule in parasitic worms can effectively treat autoimmune diseases

3SBio enters into exclusive license with DiNonA for development of Leukotuximab

Dimethyl fumarate offers no added benefits for adults with RRMS

Idera collaborates with TMA to advance new potential treatment approach for myositis

Study: Nervous system and stress affect inflammatory skin conditions

Kinex receives FDA approval to begin Phase I study of KX2-391 Ointment for actinic keratosis

Experts join together to call for better screening of psoriatic arthritis

Early-career physicians receive National Psoriasis Foundation fellowship to study psoriasis

13 researchers awarded National Psoriasis Foundation fellowship to study psoriasis

Phase III research shows that new drug improves symptoms related to plaque psoriasis

Thirteen scientists receive grant to identify new treatments, cure for psoriasis

Johnson & Johnson sales increase 9.1% to $19.5 billion in second quarter 2014

Metvix PDT now available at Odette Cancer Centre as additional treatment option for NMSC patients

Medac Pharma's Rasuvo injection gets FDA approval for RA, pJIA and psoriasis

Dmitry Medvedev presents Russia's first national "Industry" award to BIOCAD

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Psoriasis News and Research

Latest Psoriasis News and Research

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Newsletters you may be interested in